303 related articles for article (PubMed ID: 2900742)
1. Pharmacokinetics of cannabidiol in dogs.
Samara E; Bialer M; Mechoulam R
Drug Metab Dispos; 1988; 16(3):469-72. PubMed ID: 2900742
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs.
Samara E; Bialer M
Drug Metab Dispos; 1988; 16(6):875-9. PubMed ID: 2907468
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
4. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain.
Bornheim LM; Kim KY; Li J; Perotti BY; Benet LZ
Drug Metab Dispos; 1995 Aug; 23(8):825-31. PubMed ID: 7493549
[TBL] [Abstract][Full Text] [Related]
5. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
[TBL] [Abstract][Full Text] [Related]
6. Phencyclidine (PCP) disposition kinetics in dogs as a function of dose and route of administration.
Woodworth JR; Owens SM; Mayersohn M
J Pharmacol Exp Ther; 1985 Sep; 234(3):654-61. PubMed ID: 4032285
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.
Grubb MF; Wong YN; Burcham DL; Saxton PL; Quon CY; Huang SM
Drug Metab Dispos; 1994; 22(5):709-12. PubMed ID: 7835221
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs.
Usui T; Watanabe T; Higuchi S
Drug Metab Dispos; 1995 Nov; 23(11):1214-9. PubMed ID: 8591721
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.
Bartner LR; McGrath S; Rao S; Hyatt LK; Wittenburg LA
Can J Vet Res; 2018 Jul; 82(3):178-183. PubMed ID: 30026641
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers.
Paudel KS; Hammell DC; Agu RU; Valiveti S; Stinchcomb AL
Drug Dev Ind Pharm; 2010 Sep; 36(9):1088-97. PubMed ID: 20545522
[TBL] [Abstract][Full Text] [Related]
12. Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice.
Sauer JM; Bao J; Smith RL; Kuester RK; Mayersohn M; Sipes IG
Drug Metab Dispos; 1997 Oct; 25(10):1184-90. PubMed ID: 9321522
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of N-nitrosodimethylamine in beagles.
Gombar CT; Pylypiw HM; Harrington GW
Cancer Res; 1987 Jan; 47(2):343-7. PubMed ID: 3791224
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
16. Toxicokinetics of deltamethrin and its 4'-HO-metabolite in the rat.
Anadón A; Martinez-Larrañaga MR; Fernandez-Cruz ML; Diaz MJ; Fernandez MC; Martinez MA
Toxicol Appl Pharmacol; 1996 Nov; 141(1):8-16. PubMed ID: 8917670
[TBL] [Abstract][Full Text] [Related]
17. Absorption, distribution and excretion of [14C]E-4716 after single-dose administration in rats and dogs.
Serafini MT; Puig S; Pretel MJ; García A; Martínez L
Methods Find Exp Clin Pharmacol; 1997; 19(6):407-15. PubMed ID: 9385590
[TBL] [Abstract][Full Text] [Related]
18. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
[TBL] [Abstract][Full Text] [Related]
19. Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat.
Sauer JM; Smith RL; Bao J; Kattnig MJ; Kuester RK; McClure TD; Mayersohn M; Sipes IG
Drug Metab Dispos; 1997 Jun; 25(6):732-9. PubMed ID: 9193875
[TBL] [Abstract][Full Text] [Related]
20. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
